| | | | | 1 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | | January 31, 2013 | | |
Gil Labrucherie | | | | | Director | | | November 20, 2019 | | |
Nerissa Kreher, M.D. | | | | | Director | | | March 2, 2021 | | |
Philippe Fauchet | | | | | Director | | | September 10, 2020 | | |
Wladimir Hogenhuis, M.D. | | | | | Director | | | March 2, 2021 | | |
Young-Jin Kim | | | | | Director | | | February 10, 2019 | |
Total Number of Directors | | | 6 | | |||||||||
| | | Male | | | Female | | ||||||
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | | | 5 | | | | | | 1 | | |
Part II: Demographic Background | | | | | | | | | | | | | |
White | | | | | 3 | | | | | | 1 | | |
African American or Black | | | | | 1 | | | | | | — | | |
Asian | | | | | 1 | | | | | | — | | |
Did Not Disclose Demographic Background | | | | | — | | | | | | — | | |
Directors who are Military Veterans | | | | | 1 | | | | | | — | | |
| | | Committee Appointments | | |||||||||||||||
Director Name | | | Audit | | | Compensation | | | Nominating and Governance | | |||||||||
Committee Members as of June 30, | | | | | | | | | | | | | | | | | | | |
Gil Labrucherie(1) | | | | | X | ||||||||||||||
| | | | | X | | | | | | X | | | ||||||
| | | | | | | | | | X | | | | | X | | | ||
| | | | X | | | | | | X | | | | | | X | | | |
Wladimir Hogenhuis(3) | | | | | X | | | | | | X | | | | | | X | | |
Young-Jin Kim(5) | | | | | | | | | | | | | | | | | | | |
Name | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($) | | | Total ($) | | |||||||||
Gil Labrucherie | | | | | | | | | | | | | | | | | |||
Nerissa Kreher | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | | ||||
Wladimir Hogenhuis | | | | | | | | | | | | | | | | | |||
Young-Jin Kim | | | | | | | | | | | | | | | | |
| | Shares Underlying Options Outstanding | | | Shares Underlying Options Outstanding | | ||||||||||||||||||||
| | Vested | | Unvested | | | Vested | | Unvested | | ||||||||||||||||
Gil Labrucherie | | | | 8,554 | | | | | 84,446 | | | | | | 37,999 | | | | | 55,001 | | | ||||
Nerissa Kreher | | | | 33,332 | | | | | 56,668 | | | |||||||||||||||
Philippe Fauchet | | | | 5,110 | | | | | 84,890 | | | | | | 35,110 | | | | | 54,890 | | | ||||
Wladimir Hogenhuis | | | | 3,333 | | | | | 86,667 | | | | | | 33,332 | | | | | 56,668 | | | ||||
Nerissa Kreher | | | | 3,333 | | | | | 86,667 | | | |||||||||||||||
Young-Jin Kim | | | | — | | | | | 40,000 | | | | | | 13,333 | | | | | 26,667 | | |
Name of Beneficial Owner | | | Position with Company | | | Beneficial Ownership | | | Percent of Class | | ||||||
Stockholders in excess of 5% | | | | | | | | | | | | | | | | |
Entities associated with Federated Hermes, Inc. | | | Stockholder | | | | | | | | | | | | ||
Handok, Inc. | | | Stockholder | | | | | 5,942,617(2) | | | | | | | | |
| | Stockholder | | | | | | | | | | | | |||
| | Stockholder | | | | | | | | | | | | |||
Stonepine Capital Management, LLC | | | Stockholder | | | | | 2,768,656(5) | | | | | | 6.90% | | |
Directors and Executive Officers: | | | | | | | | | | | | | | | | |
Nevan Charles Elam | | | Chief Executive Officer, Acting | | | | | | | | | | | | ||
Gil Labrucherie | | | Director | | | | | |||||||||
| | | | | * | | | |||||||||
Nerissa Kreher | | | Director | | | | | | | | | | * | | | |
Philippe Fauchet | | | Director | | | | | 63,555(9) | | | | | | * | | |
Wladimir Hogenhuis | | | Director | | | | | | | | | | * | | | |
Young-Jin Kim | | | Director | | | | | | | | | | | | ||
Brian Roberts | | | Chief Medical Officer | | | | | | | | | | 1.20% | | | |
Daron Evans | | | Chief Financial Officer | | | | | 159,900(13) | | | | | | * | | |
Directors and executive officers as a group | | | | | | | | | | | | | | |
| | Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | | | Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options | | | Securities Available For Future Issuance | | |||||||||||||||||||||||||||
| Number of Shares | | Weighted Average Exercise Price | | | | Number of Shares | | Weighted Average Exercise Price | | |||||||||||||||||||||||||||||||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
2015 Non-Qualified Stock Option Plan | | February 23, 2020 | | | | 36 | | | | $ | 50.73 | | | | | — | | | | | February 23, 2020 | | | | 17 | | | | $ | 19.86 | | | | | — | | | ||||||||||
2016 Non-Qualified Stock Option Plan | | October 31, 2021 | | | | 256 | | | | | 22.77 | | | | | — | | | | | October 31, 2021 | | | | 140 | | | | | 16.62 | | | | | — | | | ||||||||||
2021 Equity Incentive Plan | | March 31, 2031 | | | | 8,014 | | | | | 4.24 | | | | | 2,686 | | | | | March 31, 2031 | | | | 8,388 | | | | | 4.09 | | | | | 2,312 | | | ||||||||||
2022 Employee Stock Purchase Plan | | Indefinite | | | | — | | | | | — | | | | | 500 | | | |||||||||||||||||||||||||||||
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
2019 Non Qualified Stock Option Plan | | July 31, 2029 | | | | 200 | | | | | 14.50 | | | | | — | | | | ||||||||||||||||||||||||||||
2019 Non-Qualified Stock Option Plan | | July 31, 2029 | | | | 200 | | | | | 14.50 | | | | | — | | | |||||||||||||||||||||||||||||
Total | | | | | | 8,506 | | | | | 5.24 | | | | | 2,686 | | | | | | | | | | 8,745 | | | | | 4.56 | | | | | 2,812 | | |
| | 2022 | | 2021 | | | 2023 | | 2022 | | ||||||||||||||||||||||||||||||||||||||||
| | Amount | | Percent | | Amount | | Percent | | | Amount | | Percent | | Amount | | Percent | | ||||||||||||||||||||||||||||||||
Audit fees(1) | | | $ | 259,000 | | | | | 85% | | | | $ | 175,500 | | | | | 82% | | | | | $ | 190,000 | | | | | 84% | | | | $ | 259,00 | | | | | 85% | | | ||||||||
Tax fees | | | | 47,225 | | | | | 15% | | | | | 38,100 | | | | | 18% | | | | | | 36,550 | | | | | 16% | | | | | 47,255 | | | | | 15% | | | ||||||||
Total | | | $ | 306,225 | | | | | 100% | | | | $ | 213,600 | | | | | 100% | | | | | $ | 226,550 | | | | | 100% | | | | $ | 306,225 | | | | | 100% | | |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | | January 31, 2013 | | |
Brian Roberts | | | | | Chief Medical Officer | | | June 1, 2022 | | |
Daron Evans | | | 50 | | | Chief Financial Officer | | | January 23, 2024 | |
Name and Position | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | |||||||||||||||
Nevan Charles Elam | | | 2022 | | | | $ | 515,000(1) | | | | | $ | 378,750(3) | | | | | $ | 6,862,960(5) | | | | | $ | 24,590(6) | | | | | $ | 7,781,300 | | |
Chief Executive Officer | | | 2021 | | | | $ | 495,682(1) | | | | | $ | 490,980(4) | | | | | $ | 3,888,117(5) | | | | | $ | 21,953(6) | | | | | $ | 4,896,732 | | |
Brian Roberts, M.D. | | | 2022 | | | | $ | 401,500(2) | | | | | $ | 121,875(3) | | | | | $ | 1,847,720(5) | | | | | $ | 52,053(7) | | | | | $ | 2,423,148 | | |
Chief Medical Officer | | | 2021 | | | | $ | 371,364(2) | | | | | $ | 171,300(4) | | | | | $ | 775,203(5) | | | | | $ | 36,074(8) | | | | | $ | 1,353,941 | | |
Name and Position(9) | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | ||||||||||||||||||
Nevan Charles Elam Chief Executive Officer | | | | | 2023 | | | | | $ | 534,112(1) | | | | | $ | 416,068(3) | | | | | $ | —(5) | | | | | $ | 23,466(6) | | | | | $ | 973,646 | | |
| | | 2022 | | | | | $ | 515,000(1) | | | | | $ | 378,750(4) | | | | | $ | 6,862,960(5) | | | | | $ | 24,590(6) | | | | | $ | 7,781,300 | | | ||
Brian Roberts, M.D. Chief Medical Officer | | | | | 2023 | | | | | $ | 457,809(2) | | | | | $ | 237,753(3) | | | | | $ | —(5) | | | | | $ | 43,296(7) | | | | | $ | 738,858 | | |
| | | 2022 | | | | | $ | 401,500(2) | | | | | $ | 121,875(4) | | | | | $ | 1,847,720(5) | | | | | $ | 52,053(8) | | | | | $ | 2,423,148 | | |
Name | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | Option Expiration Date | | |||||||||||||||||||||||||||||||||||||||||||||
| | | | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | Option Expiration Date | | ||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | | Exercisable | | Unexercisable | | | Option Exercise Price | | Option Expiration Date | | | Grant Date | | Exercisable | | Unexercisable | | | |||||||||||||||||||||||||||||||||||
| | 7/31/19 | | | | 195,833 | | | | | 4,167(1) | | | | $ | 14.50 | | | 7/31/29 | | ||||||||||||||||||||||||||||||||||||
| | 6/14/21 | | | | 125,000 | | | | | 250,000(2) | | | | | 12.28 | | | 6/14/31 | | ||||||||||||||||||||||||||||||||||||
| | 6/23/22 | | | | — | | | | | 2,600,000(4) | | | | | 3.40 | | | 6/23/32 | | ||||||||||||||||||||||||||||||||||||
Nevan Charles Elam | | | | | 7/31/19 | | | | | 200,000 | | | | | — | | | | $ | 14.50 | | | | | 7/31/29 | | | |||||||||||||||||||||||||||||
| | | 6/14/21 | | | | | 250,000 | | | | | 125,000(1) | | | | | 12.28 | | | | | 6/14/31 | | | |||||||||||||||||||||||||||||||
| | | 6/23/22 | | | | | 650,000 | | | | | 1,950,00(3) | | | | | 3.40 | | | | | 6/23/32 | | | |||||||||||||||||||||||||||||||
| | | | | 320,833 | | | | | 2,854,167 | | | | | | | | | | | | | | | | | | 1,100,000 | | | | | 2,075,000 | | | | | | | | | | | | | |||||||||||
Brian Roberts, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||
| | 7/31/19 | | | | 39,166 | | | | | 834(1) | | | | $ | 14.50 | | | 7/31/29 | | ||||||||||||||||||||||||||||||||||||
| | 6/14/21 | | | | 37,500 | | | | | 37,500(3) | | | | | 12.28 | | | 6/14/31 | | ||||||||||||||||||||||||||||||||||||
| | 6/23/22 | | | | — | | | | | 700,000(4) | | | | | 3.40 | | | 6/23/32 | | ||||||||||||||||||||||||||||||||||||
Brian Roberts, M.D. | | | | | 7/31/19 | | | | | 40,000 | | | | | — | | | | $ | 14.50 | | | | | 7/31/29 | | | |||||||||||||||||||||||||||||
| | | 6/14/21 | | | | | 56,250 | | | | | 18,750(2) | | | | | 12.28 | | | | | 6/14/31 | | | |||||||||||||||||||||||||||||||
| | | 6/23/22 | | | | | 175,00 | | | | | 525,00(3) | | | | | 3.40 | | | | | 6/23/32 | | | |||||||||||||||||||||||||||||||
| | | | | 76,666 | | | | | 738,334 | | | | | | | | | | | | | | | | | | 271,250 | | | | | 543,750 | | | | | | | | | | | | |
Pay Versus Performance | | ||||||||||||||||||||||||||||||||||||
Year(1) | | | Summary Compensation Table Total for PEO(2) | | | Compensation Actually Paid to PEO(3) | | | Average Summary Compensation Table Total for Non-PEO NEOs(2) | | | Average Compensation Actually Paid to Non-PEO NEOs(4) | | | Value of Initial Fixed $100 Investment Based On Rezolute Total Stockholder Return(5) | | | Net Income(6) | | ||||||||||||||||||
2023 | | | | $ | 973,646 | | | | | $ | (1,958,066) | | | | | $ | 738,858 | | | | | $ | (30,316) | | | | | $ | 14 | | | | | $ | (51,787,000) | | |
2022 | | | | $ | 7,781,300 | | | | | $ | 3,572,820 | | | | | $ | 2,423,148 | | | | | $ | 1,699,320 | | | | | $ | 23 | | | | | $ | (41,060,000) | | |
PEO | | ||||||||||||||||||
| | | | | | | | | 2022 | | | 2023 | | ||||||
| | | Summary Compensation Table – Total Compensation | | | (a) | | | | $ | 7,781,300 | | | | | $ | 973,646 | | |
- | | | Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year | | | (b) | | | | $ | 6,862,960 | | | | | $ | 0 | | |
+ | | | Fair Value at Covered Fiscal Year End of All Outstanding and Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year | | | (c) | | | | $ | 6,237,785 | | | | | $ | 0 | | |
+ | | | Change in Fair Value as of Prior Fiscal Year End of Any Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year | | | (d) | | | | $ | (2,393,356) | | | | | $ | (2,265,885) | | |
+ | | | Fair Value at Vesting Date of Stock Awards and Option Awards Granted in Covered Fiscal Year That Vested During Covered Fiscal Year | | | (e) | | | | $ | 0 | | | | | $ | 0 | | |
+ | | | Change in Fair Value as of Vesting Date of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year | | | (f) | | | | $ | (1,189,949) | | | | | $ | (665,827) | | |
- | | | Fair Value as of Prior Fiscal Year End of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year | | | (g) | | | | $ | 0 | | | | | $ | 0 | | |
= | | | Compensation Actually Paid | | | | | | | $ | 3,572,820 | | | | | -$ | 1,958,066 | | |
NEO Average | | ||||||||||||||||||
| | | | | | | | | 2022 | | | 2023 | | ||||||
| | | Summary Compensation Table – Total Compensation | | | (a) | | | | $ | 2,423,148 | | | | | $ | 738,858 | | |
- | | | Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year | | | (b) | | | | $ | 1,847,720 | | | | | $ | 0 | | |
+ | | | Fair Value at Covered Fiscal Year End of All Outstanding and Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year | | | (c) | | | | $ | 1,679,404 | | | | | $ | 0 | | |
+ | | | Change in Fair Value as of Prior Fiscal Year End of Any Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year | | | (d) | | | | $ | (360,815) | | | | | $ | (598,192) | | |
+ | | | Fair Value at Vesting Date of Stock Awards and Option Awards Granted in Covered Fiscal Year That Vested During Covered Fiscal Year | | | (e) | | | | $ | 0 | | | | | $ | 0 | | |
+ | | | Change in Fair Value as of Vesting Date of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year | | | (f) | | | | $ | (194,697) | | | | | $ | (170,982) | | |
- | | | Fair Value as of Prior Fiscal Year End of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year | | | (g) | | | | $ | 0 | | | | | $ | 0 | | |
= | | | Compensation Actually Paid | | | | | | | $ | 1,699,320 | | | | | $ | (30,316) | | |